Zogenix (ZGNX) Misses Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
- Qualcomm (QCOM) Reports In-Line Q4 EPS, Beats on Revenue; Offers Q1 Guidance
- Intel shares fall as competitor reports record results
- Array Technologies and Shoals Technologies agree to stock-for-stock merger
- AMD gets bullish pre-earnings call from Lynx as server CPU demand accelerates
- SanDisk shares fall on election and chip sector pressure
- After-Hours Movers: QCOM, COHR, APP, HUBS, SNAP, FSLY, FIG, ZG, BROS, CDE
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
Zogenix Provides Corporate Update and Reports First Quarter 2015 Financial Results
May 11, 2015 4:01 PM EDTSAN DIEGO, May 11, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, provided a corporate update, and announced financial results for the first quarter ended March 31, 2015.
Corporate Update
Appointed Stephen J. Farr, Ph.D., previously serving as the Company's President, as the new Chief Executive Officer of Zogenix. Dr. Farr will also continue to serve as the President of Zogenix and will remain a member of the Company's Board of Directors. Roger Hawley, the previous... More


